中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2013年
19期
38-39
,共2页
爱通立%阿替普酶%静脉溶栓%急性心肌梗死
愛通立%阿替普酶%靜脈溶栓%急性心肌梗死
애통립%아체보매%정맥용전%급성심기경사
Love Tongli%Alteplase%Intravenous thrombolysis%Acute myocardial infarction
目的：重点研究和探讨爱通立（阿替普酶）急诊静脉溶栓治疗急性心肌梗死患者的临床疗效及安全性。方法：利用回顾性分析的方法研究和比较对本院于2011年1月-2012年12月收治的30例急性心肌梗死患者的临床资料。将30例患者随机分成治疗组15例和对照组15例，治疗组采用爱通立（阿替普酶）急诊静脉溶栓进行治疗，对照组采用尿激酶急诊静脉溶栓进行治疗。比较两组患者的冠状动脉再通率和溶栓并发症发生情况。结果：治疗组治疗后的冠脉再通率比对照组低，治疗组患者治疗后的冠脉再通率为80.00%，对照组患者治疗后的冠脉再通率为73.33%，治疗组患者治疗后的溶栓并发症发生率比对照组低，两组间差异具有统计学意义（P<0.05）。结论：爱通立（阿替普酶）急诊静脉溶栓治疗急性心肌梗死具有很好的临床疗效，并且具有良好的安全性。
目的：重點研究和探討愛通立（阿替普酶）急診靜脈溶栓治療急性心肌梗死患者的臨床療效及安全性。方法：利用迴顧性分析的方法研究和比較對本院于2011年1月-2012年12月收治的30例急性心肌梗死患者的臨床資料。將30例患者隨機分成治療組15例和對照組15例，治療組採用愛通立（阿替普酶）急診靜脈溶栓進行治療，對照組採用尿激酶急診靜脈溶栓進行治療。比較兩組患者的冠狀動脈再通率和溶栓併髮癥髮生情況。結果：治療組治療後的冠脈再通率比對照組低，治療組患者治療後的冠脈再通率為80.00%，對照組患者治療後的冠脈再通率為73.33%，治療組患者治療後的溶栓併髮癥髮生率比對照組低，兩組間差異具有統計學意義（P<0.05）。結論：愛通立（阿替普酶）急診靜脈溶栓治療急性心肌梗死具有很好的臨床療效，併且具有良好的安全性。
목적：중점연구화탐토애통립（아체보매）급진정맥용전치료급성심기경사환자적림상료효급안전성。방법：이용회고성분석적방법연구화비교대본원우2011년1월-2012년12월수치적30례급성심기경사환자적림상자료。장30례환자수궤분성치료조15례화대조조15례，치료조채용애통립（아체보매）급진정맥용전진행치료，대조조채용뇨격매급진정맥용전진행치료。비교량조환자적관상동맥재통솔화용전병발증발생정황。결과：치료조치료후적관맥재통솔비대조조저，치료조환자치료후적관맥재통솔위80.00%，대조조환자치료후적관맥재통솔위73.33%，치료조환자치료후적용전병발증발생솔비대조조저，량조간차이구유통계학의의（P<0.05）。결론：애통립（아체보매）급진정맥용전치료급성심기경사구유흔호적림상료효，병차구유량호적안전성。
Objective:To focus on and discuss love Tongli(alteplase)clinical efficacy and safety of intravenous thrombolysis in patients with acute myocardial infarction.Method:Used retrospective study method to analyse and compare our hospital in 2011 January -2012 year in December 30 cases of patients with acute myocardial infarction. 30 patients were randomly divided into the treatment group of 15 cases and 15 cases in the control group,treatment group was given love Tongli(alteplase)emergency intravenous thrombolytic therapy,the control group was given urokinase intravenous thrombolysis in emergency treatment. And compared the 2 groups of patients with coronary artery recanalization rate of thrombolysis and complications. Result:The recanalization rate was lower than the control group in treatment of coronary artery in patients after treatment,treatment of coronary artery in the patients with recanalization rate was 80.00%,control group patients after coronary artery recanalization rate was 73.33%,complications of thrombolytic therapy group were lower than those in the control group the incidence of. Differences between the two groups was significant,there was statistical significance(P<0.05).Conclusion:Love Tongli(alteplase)emergency intravenous thrombolytic therapy has good clinical efficacy in treatment of acute myocardial infarction,and has good security.
